Drug Profile
BST 1002
Latest Information Update: 19 May 2001
Price :
$50
*
At a glance
- Originator BioStratum
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer metastases
Most Recent Events
- 19 May 2001 Discontinued-Preclinical for Cancer metastases in USA (Unknown route)
- 03 May 1997 Preclinical development for Cancer metastases in USA (Unknown route)